KalVista Pharmaceuticals (KALV) Retained Earnings (2014 - 2025)
KalVista Pharmaceuticals (KALV) reported Retained Earnings of -$6.4 million for Q3 2025, up 98.75% on a YoY basis from -$3.2 million in Q3 2024, and down 22.5% sequentially from -$5.2 million in Q2 2025.
KalVista Pharmaceuticals (KALV) Retained Earnings (2014 - 2025) Analysis & Trends
KalVista Pharmaceuticals (KALV) has 12 years of Retained Earnings data on file, last reported at -$6.4 million in Q3 2025.
- For the quarter ending Q3 2025, Retained Earnings rose 98.75% year-over-year to -$6.4 million; the trailing twelve-month figure through Jul 2025 stood at -$6.4 million (up 98.75% YoY), and the FY2025 full-year result was -$5.2 million, up 98.89% from the prior year.
- Retained Earnings slipped to -$6.4 million in Q3 2025, from -$5.2 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$2.3 million in Q1 2022 to a low of -$580.2 million in Q4 2024.
- A 5-year average of -$214.3 million and a median of -$183.9 million in 2021 frame the typical range for Retained Earnings.
- Peak annual rise in Retained Earnings reached 99.32% in 2024, while the deepest fall reached 17546.8% in 2024.
- Tracing KALV's Retained Earnings over 5 years: stood at -$203.6 million in 2021, then sank by 45.14% to -$295.5 million in 2022, then sank by 34.03% to -$396.0 million in 2023, then tumbled by 46.49% to -$580.2 million in 2024, then soared by 98.9% to -$6.4 million in 2025.
- Business Quant data shows KALV's Retained Earnings at -$6.4 million in Q3 2025, -$5.2 million in Q2 2025, and -$580.2 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn | -6.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -6.39 Mn |
| Apr 30, 2025 | -5.21 Mn |
| Dec 31, 2024 | -580.18 Mn |
| Oct 31, 2024 | -2.70 Mn |
| Jul 31, 2024 | -510.17 Mn |
| Apr 30, 2024 | -469.73 Mn |
| Jan 31, 2024 | -425.10 Mn |
| Oct 31, 2023 | -396.05 Mn |
| Jul 31, 2023 | -2.89 Mn |
| Apr 30, 2023 | -343.08 Mn |
| Jan 31, 2023 | -316.80 Mn |
| Oct 31, 2022 | -295.50 Mn |
| Jul 31, 2022 | -4.15 Mn |
| Apr 30, 2022 | -3.86 Mn |
| Jan 31, 2022 | -2.34 Mn |
| Oct 31, 2021 | -203.60 Mn |
| Jul 31, 2021 | -183.95 Mn |
| Apr 30, 2021 | -167.84 Mn |
| Jan 31, 2021 | -152.88 Mn |
| Oct 31, 2020 | -142.83 Mn |